Citadel Advisors’s Phaxiam Therapeutics PHXM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-1,661
Closed -$12.1K – 15390
2023
Q2
$12.1K Buy
1,661
+580
+54% +$5.1K ﹤0.01% 13097
2023
Q1
$10.6K Sell
1,081
-2,678
-71% -$20.7K ﹤0.01% 13522
2022
Q4
$12.4K Buy
3,759
+1,941
+107% +$11.4K ﹤0.01% 13507
2022
Q3
$10K Sell
1,818
-5,211
-74% -$51.6K ﹤0.01% 12284
2022
Q2
$77K Buy
7,029
+3,632
+107% +$44.9K ﹤0.01% 11632
2022
Q1
$62K Sell
3,397
-3,936
-54% -$74.4K ﹤0.01% 12660
2021
Q4
$173K Buy
7,333
+5,876
+403% +$198K ﹤0.01% 12072
2021
Q3
$84K Buy
+1,457
New +$81.6K ﹤0.01% 13032
2021
Q2
– Sell
-1,134
Closed -$81K – 14650
2021
Q1
$81K Buy
+1,134
New +$105K ﹤0.01% 12628

Other funds holding PHXM

Citadel Advisors's PHXM Position: Q3 2023 in Review

Citadel Advisors sold out of Phaxiam Therapeutics (PHXM) in Q3 2023, closing a stake of 1,661 shares — an estimated $12.1K sold.

Citadel Advisors first reported a position in PHXM in Q1 2021 and held it in 9 quarters. The position peaked at $173K in Q4 2021. 3 funds tracked by Wall St. Rank hold PHXM as of Q3 2023.

  • Citadel Advisors reported no remaining Phaxiam Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,661 Phaxiam Therapeutics shares in Q3 2023, an estimated $12.1K.
  • Citadel Advisors first reported a position in Phaxiam Therapeutics in Q1 2021 and held it in 9 quarters.
  • Citadel Advisors's Phaxiam Therapeutics position peaked at $173K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.